Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Molecular therapies for tuberous sclerosis and neurofibromatosis.

Franz DN, Weiss BD.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):294-301. doi: 10.1007/s11910-012-0269-4. Review.

PMID:
22544507
2.

Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.

Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M.

Hum Genomics. 2011 Oct;5(6):623-90. Review.

3.

The early history of the neurofibromatosis. Evolution of the concept of neurofibromatosis type 2.

Ahn MS, Jackler RK, Lustig LR.

Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1240-9.

PMID:
8906061
4.

CAPE (caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice.

Demestre M, Messerli SM, Celli N, Shahhossini M, Kluwe L, Mautner V, Maruta H.

Phytother Res. 2009 Feb;23(2):226-30. doi: 10.1002/ptr.2594.

PMID:
18726924
5.

Neurofibromatosis type 1.

Boyd KP, Korf BR, Theos A.

J Am Acad Dermatol. 2009 Jul;61(1):1-14; quiz 15-6. doi: 10.1016/j.jaad.2008.12.051. Review.

6.

The pathoetiology of neurofibromatosis 1.

Jouhilahti EM, Peltonen S, Heape AM, Peltonen J.

Am J Pathol. 2011 May;178(5):1932-9. doi: 10.1016/j.ajpath.2010.12.056. Epub 2011 Mar 31. Review.

7.

Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Evans DG.

Orphanet J Rare Dis. 2009 Jun 19;4:16. doi: 10.1186/1750-1172-4-16. Review.

8.

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A.

J Med Genet. 2007 Feb;44(2):81-8. Epub 2006 Nov 14. Review.

9.

Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D, Lloyd AC, Mayes DA, Messiaen L, Morrison H, North K, Packer R, Pan D, Stemmer-Rachamimov A, Upadhyaya M, Viskochil D, Wallace MR, Hunter-Schaedle K, Ratner N.

Acta Neuropathol. 2012 Mar;123(3):369-80. doi: 10.1007/s00401-011-0905-0. Epub 2011 Nov 16.

10.

Clinical and genetic aspects of neurofibromatosis 1.

Jett K, Friedman JM.

Genet Med. 2010 Jan;12(1):1-11. doi: 10.1097/GIM.0b013e3181bf15e3. Review.

PMID:
20027112
11.

Management of pregnancy in women with genetic disorders: Part 2: Inborn errors of metabolism, cystic fibrosis, neurofibromatosis type 1, and Turner syndrome in pregnancy.

Chetty SP, Shaffer BL, Norton ME.

Obstet Gynecol Surv. 2011 Dec;66(12):765-76. doi: 10.1097/OGX.0b013e31823cdd7d. Review.

PMID:
22192461
12.

Neurofibromatosis and pregnancy. An update.

Weissman A, Jakobi P, Zaidise I, Drugan A.

J Reprod Med. 1993 Nov;38(11):890-6. Review.

PMID:
8277488
13.

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

Listernick R, Ferner RE, Liu GT, Gutmann DH.

Ann Neurol. 2007 Mar;61(3):189-98. Review.

PMID:
17387725
14.

Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.

Davidson TB, Sanchez-Lara PA, Randolph LM, Krieger MD, Wu SQ, Panigrahy A, Shimada H, Erdreich-Epstein A.

BMC Med Genet. 2012 Mar 22;13:19. doi: 10.1186/1471-2350-13-19. Review.

15.

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, Kurzrock R.

J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27. No abstract available.

16.
17.

Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.

Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, Ligon KL, Epstein JA, Look AT.

Dis Model Mech. 2012 Nov;5(6):881-94. doi: 10.1242/dmm.009779. Epub 2012 Jul 5.

18.

Neurofibromatosis type 1 revisited.

Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL.

Pediatrics. 2009 Jan;123(1):124-33. doi: 10.1542/peds.2007-3204. Review.

PMID:
19117870
19.
20.

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner.

Banerjee S, Crouse NR, Emnett RJ, Gianino SM, Gutmann DH.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15996-6001. doi: 10.1073/pnas.1019012108. Epub 2011 Sep 6.

Supplemental Content

Support Center